HT-1376Homo sapiens (Human)Cancer cell line

Also known as: HT 1376.T, HT 1376, HT1376, HT-137, HT-1367

🤖 AI SummaryBased on 14 publications

Quick Overview

Bladder cancer cell line with known mutations and genomic alterations.

Detailed Summary

HT-1376 is a bladder cancer cell line derived from a transitional cell carcinoma. It is widely used in research due to its well-characterized genetic profile, including mutations in key oncogenes and tumor suppressor genes. The cell line exhibits specific genomic alterations such as homozygous deletions and mutations in genes like CDKN2, CDKN2B, and MTAP, which are associated with cell cycle regulation and tumor suppression. HT-1376 has been utilized in studies investigating the molecular mechanisms of bladder cancer, including the role of TSC1 and TSC2 in tumor progression. Research on HT-1376 has contributed to understanding the genetic basis of bladder cancer and has been instrumental in developing targeted therapies. The cell line is also used to study drug resistance mechanisms and to evaluate the efficacy of various chemotherapeutic agents.

Research Applications

Genomic and molecular characterization of bladder cancerInvestigation of tumor suppressor gene mutationsStudy of drug resistance mechanismsEvaluation of chemotherapeutic efficacy

Key Characteristics

Homozygous deletions in CDKN2, CDKN2B, and MTAPMutations in TSC1 and TSC2Expression of p16 and p15 proteinsSensitivity to mTOR inhibitors
Generated on 6/16/2025

Basic Information

Database IDCVCL_1292
SpeciesHomo sapiens (Human)
Tissue SourceUrinary bladder[UBERON:UBERON_0001255]

Donor Information

Age58
Age CategoryAdult
SexFemale
Racecaucasian

Disease Information

DiseaseBladder carcinoma
LineageBladder/Urinary Tract
SubtypeBladder Urothelial Carcinoma
OncoTree CodeBLCA

DepMap Information

Source TypeATCC
Source IDACH-000724_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Pro250Leu (c.749C>T)Heterozygous-PubMed=22570425
MutationSimpleTERTc.1-124C>T (c.228C>T) (C228T)UnspecifiedIn promoterfrom parent cell line Hep-G2
MutationSimpleRB1p.Gln702Ter (c.2104C>T)Homozygous-from parent cell line HT-1376

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
12
D13S317
9,11
D16S539
11,14
D18S51
14,15
D19S433
16
D21S11
26,32.2
D2S1338
17,19
D3S1358
14,17
D5S818
11,12
D7S820
9,12
D8S1179
14,16
FGA
21,22
Penta D
11
Penta E
7,13
TH01
7,9.3
TPOX
8
vWA
15,18
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Systematic review: characteristics and preclinical uses of bladder cancer cell lines.

Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.

Bladder Cancer 4:169-183(2018).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.

Tsang S.X., Cai Z.-M., Wu S., Dean M., Costello J.C., Theodorescu D.

Oncogene 36:35-46(2017).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics.

Limbart D.M., Rodel F., Wezel F., Haferkamp A., Cinatl J. Jr.

Transl. Oncol. 8:210-216(2015).

The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.

Chanock S.J., Valencia A., Real F.X.

BMC Genomics 16:403.1-403.16(2015).

Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer.

Oliveira P., Santos L.

Tumor Biol. 35:4599-4617(2014).

Identification of mutations in distinct regions of p85 alpha in urothelial cancer.

Knowles M.A.

PLoS ONE 8:E84411-E84411(2013).

Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.

Hurst C.D., Platt F.M., Knowles M.A.

Eur. Urol. 65:367-369(2014).

TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.

Kwiatkowski D.J.

J. Pathol. 230:17-27(2013).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Short tandem repeat profiling provides an international reference standard for human cell lines.

Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.

Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).

Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer.

Markl I.D.C., Jones P.A.

Cancer Res. 58:5348-5353(1998).

The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes.

Stadler W.M., Olopade O.I.

Urol. Res. 24:239-244(1996).

p53 mutations in bladder carcinoma cell lines.";

Lippa M., Hatzivassiliou G., Tan J.

Oncol. Res. 6:569-579(1994).

Human urologic cancer cell lines.";

Williams R.D.

Invest. Urol. 17:359-363(1980).

Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines.

Franks L.M.

Cancer Res. 46:3630-3636(1986).

Human tumor lines for cancer research.";

Fogh J.

Cancer Invest. 4:157-184(1986).

Human bladder carcinoma: characterization of two new tumor cell lines and search for tumor viruses.

Rasheed S., Gardner M.B., Rongey R.W., Nelson-Rees W.A., Arnstein P.

J. Natl. Cancer Inst. 58:881-890(1977).

Web Resources